Connect your AI

Precigen PGEN Change in receivables

Change in receivables at other companies

Bristol-Myers SquibbBMY

-$1.69B-11,147%

Other financials

Income statement

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

Market cap$1.91B+213%

Enterprise value$2B+234%

P/S72×—

Profitability

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Precigen's change in receivables?: Precigen (PGEN) reported change in receivables of -$144K in Q1 2026.
How has Precigen's change in receivables changed year-over-year?: Precigen's change in receivables decreased by 289.5% year-over-year, from $76K to -$144K.
What does change in receivables mean?: Change in total receivables including trade and non-trade receivables.